Table 2.
The number of detected biomarkers in synovial fluid, serum and vendor plasma samples.
| Synovial fluid | Serum | Vendor plasma QC | |
|---|---|---|---|
| Biomarkers: | |||
| Detected in ≥75% of samples, n | 60 | 73 | 67, 72 |
| Detected in >90% of samples, n | 50 | 68 | 67, 71 |
| Detected in 0% of samples, n | 1 | 1 | 11, 14 |
| aExperiments, n | 1 | 1 | 2 |
| Plates, n | 12 | 19 | 12, 19 |
| Samples for analyses, n (dilution) | 1014 (4x) | 1656 (1x) | 24 (1x), 38 (1x) |
| bSamples that passed QC, n (%) | 998 (98.4) | 1622 (97.9) | 24 (100), 38 (100) |
| cSamples that failed, n, (%) | 7 (0.7) | 0 (0) | 0 (0) |
| Sampled that did not pass QC, n (%) | 9 (0.9) | 34 (2.1) | 0 (0) |
a
Experiments = analyses done at one or two different occasions at Olink.
b
Samples that passed quality control (QC) of vendor and that had data values above lower limit of detection.
c
Seven synovial fluid samples lacked data for all 92 biomarkers.